Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder

被引：3
|
作者：
Kawahara, Takashi [1 ]
Nishiyama, Hiroyuki [1 ]
Yamamoto, Shingo [1 ]
Kamoto, Toshiyuki [1 ]
Ogawa, Osamu [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2006年 / 13卷 / 09期
关键词：
bladder tumor; irinotecan; small cell carcinoma;
D O I：
10.1111/j.1442-2042.2006.01521.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A 73-year-old man with primary small-cell carcinoma of the bladder was treated by radical cystectomy with neoadjuvant chemotherapy. Pathological complete remission was achieved by combination chemotherapy composed of cisplatin, etoposide and irinotecan. The patient is free of disease 19 months after surgery.
引用
收藏
页码：1251 / 1253
页数：3
相关论文
共 50 条
  • [31] Primary small cell carcinoma of the urinary bladder
    Qayoom, Sumaira
    Chakrabarti, Deep
    Khan, Fatima
    Goel, Madhu Mati
    BMJ CASE REPORTS, 2019, 12 (09)
  • [32] Primary small cell carcinoma of the bladder.
    Tiguert, R
    Ravery, V
    Gheiler, EL
    Grignon, DJ
    Gudziak, MR
    Wood, DP
    Pontes, JE
    PROGRES EN UROLOGIE, 1999, 9 (02): : 256 - 260
  • [33] Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer
    Okuma, Hitomi Sumiyoshi
    Horinouchi, Hidehito
    Kitahara, Shinsuke
    Asao, Tetsuhiko
    Sunami, Kuniko
    Goto, Yasushi
    Kanda, Shintaro
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2017, 18 (02) : 234 - +
  • [34] BLADDER PRESERVATION AND DURABLE COMPLETE REMISSION OF SMALL-CELL CARCINOMA OF THE BLADDER WITH SYSTEMIC CHEMOTHERAPY AND ADJUVANT RADIATION-THERAPY
    OBLON, DJ
    PARSONS, JT
    ZANDER, DS
    WAJSMAN, Z
    CANCER, 1993, 71 (08) : 2581 - 2584
  • [35] COMBINATION CHEMOTHERAPY WITH CISPLATIN, ETOPOSIDE AND ADRIAMYCIN IN SMALL CELL BRONCHOGENIC-CARCINOMA
    NICAISE, C
    KLASTERSKY, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) : 240 - 240
  • [36] SMALL-CELL CARCINOMA OF THE CERVIX TREATED WITH CONCURRENT RADIOTHERAPY, CISPLATIN, AND ETOPOSIDE
    HOSKINS, PJ
    WONG, F
    SWENERTON, KD
    PIKE, JA
    MANJI, M
    MCMURTRIE, E
    ACKER, B
    LERICHE, J
    GYNECOLOGIC ONCOLOGY, 1995, 56 (02) : 218 - 225
  • [37] Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
    Xiao, Xiaoguang
    Wang, Shujing
    Xia, Shu
    Zou, Man
    Li, Yang
    Wei, Yao
    Mei, Qi
    Chen, Yuan
    ONCOTARGETS AND THERAPY, 2015, 8 : 2209 - 2214
  • [38] Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature
    Funakoshi, Shinsuke
    Hashiguchi, Akinori
    Teramoto, Kana
    Miyata, Naoteru
    Kurita, Satoshi
    Adachi, Masayuki
    Hamamoto, Yasuo
    Higuchi, Hajime
    Takaishi, Hiromasa
    Hibi, Toshifumi
    ONCOLOGY LETTERS, 2013, 5 (01) : 117 - 122
  • [39] CISPLATIN AND ETOPOSIDE COMBINATION CHEMOTHERAPY FOR REFRACTORY SMALL CELL-CARCINOMA OF THE LUNG
    PORTER, LL
    JOHNSON, DH
    HAINSWORTH, JD
    HANDE, KR
    GRECO, FA
    CANCER TREATMENT REPORTS, 1985, 69 (05): : 479 - 481
  • [40] Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis
    Jiang, Lei
    Yang, Ke-Hu
    Mi, Deng-hai
    Liu, Ya-Li
    Tian, Jin-Hui
    Ma, Bin
    Tan, Ji-Ying
    Bai, Zheng-Gang
    CLINICAL LUNG CANCER, 2007, 8 (08) : 497 - 501
12345